Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Cure Genetics develops two biotechnology platforms: AIMS CAR-NKT, a cell therapy targeting solid tumors such as clear cell renal carcinoma, and the VELP directed-evolution library platform for gene therapy applications addressing the nervous system, heart, and kidneys. Its VELP platform has licensing collaborations with pharmaceutical companies including Boehringer Ingelheim.
2 investors
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets. Its pipeline focuses on cancer, immunology, and inflammation.
2 investors
Acquired by Horizon Therapeutics in 2020.
2 investors
Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
2 investors
Cyclana Bio is a biotech company developing therapeutic programs focused on the extracellular matrix and tissue-level disease biology, with a flagship focus on women's health conditions such as endometriosis. Based at the Babraham Research Campus in Cambridge, UK, its work builds on academic research into how the non-cellular component of tissue drives health and disease.
2 investors
Cytel provides software and biometrics solutions for clinical trial design and delivery in the life sciences industry. The company serves pharmaceutical companies sponsoring clinical trials and their biometrics and biostatistics teams.
2 investors
CytoGen Lab develops liquid biopsy technology for cancer detection through circulating tumor cell (CTC) isolation from blood samples, combining biotechnology and engineering for precision medicine applications.
2 investors
Cytoki Pharma is a clinical-stage biotechnology company developing IL-22-based medicines for metabolic diseases such as obesity and type 2 diabetes, and conditions involving epithelial injury like inflammatory bowel disease. Its lead candidate, CK-0045, is a long-acting IL-22 analogue in Phase 2 clinical evaluation for cardiometabolic diseases.
2 investors
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue. Based on research from Yale University, its pipeline includes an androgen receptor inhibitor for early-stage prostate cancer and additional inhibitors for breast and other cancers.
2 investors
Cytotrait develops genetic technologies for crop improvement through chloroplast engineering. The company applies proprietary MOSS technology to enable precise DNA mutagenesis in plant genomes for agricultural biotechnology applications.
2 investors
Cytotronics develops Pixel, a semiconductor-to-live-cell interface platform that measures cell viability, morphology, electrophysiology, and metabolism at single-cell resolution across any cell type or 3D organoid system. It serves cell biologists working in therapeutic areas such as vascular biology, stem cell differentiation, cardiovascular and neurological disease, and oncology.
2 investors
D-NOME develops molecular reagent technologies aimed at making diagnostics more affordable and accessible. Founded in 2021, the company builds bio-technologies for the diagnostics and healthcare sector.
2 investors
Daisy Lab develops precision fermentation food technology to produce dairy proteins without animals. The company is based in New Zealand.
2 investors
Dalan develops vaccines that work with animals' natural immune defenses to protect against disease, with products including a USDA-approved honeybee vaccine and a shrimp vaccine in development. The company operates in the bioscience and animal health sector, serving agriculture and aquaculture markets.
2 investors
DataJoint builds data platforms and infrastructure for scientific operations, enabling researchers and organizations to create reproducible, scalable, and traceable research workflows powered by AI and automation.
2 investors
DEEP Measures enables the adoption of harmonized digital health measures across the pharmaceutical, tech, and regulatory ecosystem. The company connects pharma companies, technology providers, and regulators to collaboratively develop and deploy digital solutions for clinical research and health measurement.
2 investors
DeepMirror develops AI software for hit-to-candidate molecule design in drug discovery, enabling teams to generate novel chemical candidates and predict molecular properties using proprietary data while maintaining strict data privacy and IP security.
2 investors
DeepSeq designs biologic drugs using AI trained on massive datasets of real protein interactions, predicting properties such as affinity, specificity, immunogenicity, pharmacokinetics, and manufacturability. It aims to accelerate the development of better biologic therapeutics for patients.
2 investors
2 investors
Delineate builds AI agents that help pharmaceutical companies design clinical trials more quickly by converting existing trial research into specialized datasets, reducing the time scientists spend on trial preparation.
2 investors
Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.
2 investors
Delpor develops subcutaneous implant devices that deliver therapeutic drugs over extended periods (6-12 months) for chronic condition treatment. The company's passive implant technology enables sustained-release drug delivery through simple in-office procedures, targeting improved patient adherence and consistent pharmacokinetic profiles.
2 investors
Enables people to live more deliberate lives through data-driven insights
2 investors
AMR Bio is a clinical-phase biotechnology company developing novel anti-infective drugs focused on infection prevention and combating antibiotic resistance.
2 investors